AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/refractory multiple myeloma.